Skip to content

US · TPST · BIOTECHNOLOGY

Tempest Therapeutics, Inc. (TPST) intrinsic value and stock valuation

$0.29as of 2026-11-21 · Mkt cap 4.07M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tempest Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values TPST with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TPST’s statements →

Tempest Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Brisbane, CA 94005 tempesttx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-26.26M
20112025
Free cash flow
-$-26.82M
20122025
Total equity
$6.67M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-26.57M-$-42.03M-$-29.16M-$-34.64M-$-26.99M
Net income-$-26.26M-$-41.84M-$-29.49M-$-35.71M-$-28.3M
EPSd-$-6.33M-$-1.5M-$-1.91M-$-40.12M-$-97.59M
Operating cash flow-$-26.82M-$-33.03M-$-27.36M-$-31.07M-$-25.96M
Capital expenditure$0.00-$-430K-$-170K-$-560K-$-140K
Free cash flow-$-26.82M-$-33.46M-$-27.53M-$-31.63M-$-26.09M
Total assets$16.9M$41.5M$51.6M$46.1M$73.2M
Total debt$8.14M$15.4M$20.7M$22.1M$18.5M
Net debt$430K-$-14.9M-$-18.57M-$-9.12M-$-33.29M
Total equity$6.67M$19.1M$26.8M$18.1M$36.1M
Cash and short-term investments$7.71M$30.3M$39.2M$31.2M$51.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$390K$0.00$0.00$0.00
Gross profit$0.00-$-390K$0.00$0.00$0.00
Research and development expenses$12.6M$28.5M$17.5M$22.5M$17.2M
Selling, general and administrative expenses$14M$13.6M$11.7M$12.1M$9.82M
Other expenses$0.00-$-390K$0.00$0.00$0.00
Operating expenses$26.6M$41.6M$29.2M$34.6M$27M
Cost and expenses$26.6M$42M$29.2M$34.6M$27M
Interest income$520K$1.5M$1.11M$550K$0.00
Interest expense$210K$1.32M$1.45M$1.62M$1.28M
Depreciation and amortization$270K$390K$380K$640K$370K
Ebitda-$-25.79M-$-40.14M-$-27.66M-$-33.45M-$-26.65M
Operating income-$-26.57M-$-42.03M-$-29.16M-$-34.64M-$-26.99M
Total other income/expenses, net$310K$180K-$-330K-$-1.07M-$-1.32M
Income before tax-$-26.26M-$-41.84M-$-29.49M-$-35.71M-$-28.3M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-26.26M-$-41.84M-$-29.49M-$-35.71M-$-28.3M
Weighted average shares outstanding$4.15M$27.9M$15.4M$890K$290K
Weighted average diluted shares outstanding$4.15M$27.9M$15.4M$890K$290K
Balance sheet
20252024202320222021
Cash and short-term investments$7.71M$30.3M$39.2M$31.2M$51.8M
Net receivables$0.00$0.00$0.00$450K$15M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.27M$31.5M$40.4M$33M$69M
Property, plant and equipment, net$8.14M$9.53M$10.8M$12.7M$4.16M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$390K$0.00$0.00$0.00
Total non-current assets$8.66M$10M$11.2M$13.1M$4.28M
Total assets$16.9M$41.5M$51.6M$46.1M$73.2M
Accounts payable$1.04M$2.45M$840K$1.11M$990K
Short-term debt$1.19M$7.22M$5.24M$1.41M$1.44M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.31M$14.2M$9.41M$7.28M$20M
Long-term debt$6.95M$8.14M$15.4M$20.7M$17.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$6.95M$8.14M$15.4M$20.7M$17.1M
Capital lease obligations$1.19M$9.01M$10.1M$11.7M$3.47M
Total liabilities$10.3M$22.4M$24.8M$28M$37.1M
Common stock$10K$40K$20K$10K$10K
Retained earnings-$-233.37M-$-207.11M-$-165.26M-$-135.77M-$-100.06M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$6.67M$19.1M$26.8M$18.1M$36.1M
Total investments$0.00$390K$0.00$0.00$0.00
Total debt$8.14M$15.4M$20.7M$22.1M$18.5M
Net debt$430K-$-14.9M-$-18.57M-$-9.12M-$-33.29M
Cash flow statement
20252024202320222021
Net income-$-26.26M-$-41.84M-$-29.49M-$-35.71M-$-28.3M
Depreciation and amortization$270K$390K$380K$640K$370K
Stock-based compensation$3.12M$5.3M$2.55M$1.56M$1.1M
Change in working capital-$-5.13M$1.61M-$-2.68M$870K-$-610K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.41M$1.6M-$-260K$0.00-$-210K
Net cash provided by operating activities-$-26.82M-$-33.03M-$-27.36M-$-31.07M-$-25.96M
Investments in property, plant and equipment$0.00-$-430K-$-170K-$-560K-$-140K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00-$-430K-$-170K-$-560K-$-100K
Common stock issued$10.7M$28.6M$35.6M$8.86M$33.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$4.26M$24.5M$35.6M$11.4M$59.1M
Net change in cash-$-22.56M-$-8.96M$8.07M-$-20.23M$33M
Cash at end of period$8.15M$30.7M$39.7M$31.6M$51.8M
Operating cash flow-$-26.82M-$-33.03M-$-27.36M-$-31.07M-$-25.96M
Capital expenditure$0.00-$-430K-$-170K-$-560K-$-140K
Free cash flow-$-26.82M-$-33.46M-$-27.53M-$-31.63M-$-26.09M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tempest Therapeutics, Inc.

        Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.

        CEO
        Matthew Angel
        Employees
        4
        Beta
        -1.71

        Explore

        Frequently asked questions

        What is the intrinsic value of Tempest Therapeutics, Inc. (TPST)?

        InvestorsCraft does not currently publish an intrinsic value for TPST. How the IC value is calculated.

        Is TPST undervalued?

        InvestorsCraft does not publish an undervaluation signal for TPST at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.